REVIEW Polo-like kinase 1 (Plk1) is a regulator of the cell cycle that has been implicated in the pathology of many cancers. BI-2536 is a potent and selective small-molecule inhibitor of mammalian Plk1. It has inhibitory activity at subnanomolar concentrations and inhibits tumor growth in multiple tumor lines with IC50 values below 1 µM. BI-2536 also shows an >1,000-fold selectivity for PIK1 versus a large panel of other kinases. BI-2536 also demonstrated low Kd values against sister kinases PLK2 and PLK3. Preclinical studies in human cancer cell lines have shown that BI 2536 disrupts spindle assembly, resulting in mitotic arrest and inducing apoptosis. BI-2536 is currently in clinical trials against several types of solid tumor cancers.
All in-stock products are shipped from San Francisco Bay Area, California, USA.
⚠️
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.